Evidence map›Paper›PMID 41152849›Full record

ArticleCost effectiveness and resource allocation : C/E2025

The crucial role of early diagnosis for patients and the nation, understanding the costs of late-stage cancer diagnosis from a large district general hospital in England.

Valentin Butnari, Petra Scantlebury, Tony Green, Devendra Pattni, Ahmer Mansuri, Wendy Chinnery, Nirooshun Rajendran, Mike Brannan, Matthew Cole, Saswata Banerjee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cost effectiveness and resource allocation : C/E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valentin Butnari *National Bowel Research Center, The Center for Neuroscience, Surgery and Trauma, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK. v.butnari@qmul.ac.uk.ORCID http://orcid.org/0000-0001-8995-0413
Petra Scantlebury *Department of Finance, Strategy, Insight and Delivery, Barking, Havering and Redbridge University NHS Trust, London, UK.
Tony GreenDepartment of Finance, Strategy, Insight and Delivery, Barking, Havering and Redbridge University NHS Trust, London, UK.
Devendra PattniDepartment of Finance, Strategy, Insight and Delivery, Barking, Havering and Redbridge University NHS Trust, London, UK.
Ahmer MansuriDepartment of Surgery, Barking, Havering and Redbridge University NHS Trust, London, UK.
Wendy ChinneryDepartment of Cancer Performance, Improvement & Data, Barking, Havering and Redbridge University NHS Trust, London, UK.
Nirooshun RajendranNational Bowel Research Center, The Center for Neuroscience, Surgery and Trauma, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.
Mike BrannanDepartment of Public Health, London Borough of Barking and Dagenham, London, UK.
Matthew ColeDepartment of Public Health, London Borough of Barking and Dagenham, London, UK.
Saswata BanerjeeDepartment of Surgery, Barking, Havering and Redbridge University NHS Trust, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEarly cancer diagnosis is crucial in improving the survival. The main goal in NHS in cancer diagnosis is detection rate of 75% by 2028. Our study presents the economic analysis of impact of early versus late-cancer diagnosis on healthcare resources use and costs within our Trust also exploring the influence of deprivation index.

methodsWe retrospectively analyse the cost-of-care and patient-level data for 4596 patients across nine cancer groups who fully completed their cancer pathway between April 2020 and September 2024. Costs were compared between early (stage 1 and 2) versus late (stage 3 and 4) diagnosis.

resultsSignificant variations in costs were determine across cancer types, with colorectal and haematological malignancies being most costly. Early-stage diagnosis averaged £11,2K, significantly lower than late- stage £23,8K with largest differences seen in haematological, colorectal and breast cancers. A hypothetical 75% early detection rate could save the trust £14.7 million over four years. Successful treatment yielded an average 10.74 years of healthy life expectancy, further increased by early detection.

conclusionsLate cancer diagnosis dramatically increases healthcare costs underscoring the importance of early detection and advanced screening methods. Extrapolating a 75% early detection rate across the NHS could yield substantial financial savings, highlighting its impact on healthcare efficiency.

Indexed as

CancerClaimsCostDiagnosisEconomic burdenFinancial burdenStage

Identifiers

PMID41152849
PMCPMC12570495

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.